Ionis highlights achievements, commercial strategy and technology advancements at Investor Day
The Pharma Data
DECEMBER 8, 2020
It was also announced that Akcea is going to commercialize TEGSEDI and WAYLIVRA in Europe through a distribution agreement with Swedish Orphan Biovitrum AB (“Sobi”), an international biopharmaceutical company that focuses on rare diseases. Therefore, Ionis and AstraZeneca have decided to terminate the Phase 1 PCSK9 oral study.
52 
Let's personalize your content